Preclinical Pharmacology of GW280430A (AV430A) in the Rhesus Monkey and in the Cat

Abstract

These experiments show a much shorter neuromuscular blocking effect and much-reduced side effects in the case of GW280430A vis-à-vis mivacurium. These results, together with the novel chemical degradation of GW280430A, suggest further evaluation in human subjects.